Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus ULTRATAG.
SODIUM IODIDE I 123 vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
NOT FOUND
None Documented
None Documented
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical